| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938357 |
| Molecular Weight (Da) | 335 |
| SMILES | CCCCCn1c2ccccc2c2cc(CN3CCCCC3)ccc21 |
| Molecular Formula | C23N2 |
| Action | Agonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938357 |
| Molecular Weight (Da) | 335 |
| SMILES | CCCCCn1c2ccccc2c2cc(CN3CCCCC3)ccc21 |
| Molecular Formula | C23N2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938357 |
| Molar Refractivity | 105.159 |
| HBA | 0 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 25 |
| LogP | 6.214 |
| Activity (Ki) in nM | 371.535 |
| Polar Surface Area (PSA) | 8.17 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000096938357 |
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | + |
| Bsep inhibitor | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.05340492 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 13 |
| Fraction csp3 | 0.48 |
| Ilogp | 4.34 |
| Xlogp3 | 5.75 |
| Wlogp | 5.44 |
| Mlogp | 4.54 |
| Silicos-it log p | 5.44 |
| Consensus log p | 5.1 |
| Esol log s | -5.53 |
| Esol solubility (mg/ml) | 0.000998 |
| Esol solubility (mol/l) | 0.00000298 |
| Esol class | Moderately |
| Ali log s | -5.69 |
| Ali solubility (mg/ml) | 0.000684 |
| Ali solubility (mol/l) | 0.00000204 |
| Ali class | Moderately |
| Silicos-it logsw | -7.24 |
| Silicos-it solubility (mg/ml) | 0.0000193 |
| Silicos-it solubility (mol/l) | 5.77E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.26 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 2.23 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -5.651 |
| Logd | 4.517 |
| Logp | 6.043 |
| F (20%) | 0.611 |
| F (30%) | 0.726 |
| Mdck | 9.79E-06 |
| Ppb | 0.9517 |
| Vdss | 2.949 |
| Fu | 0.018 |
| Cyp1a2-inh | 0.522 |
| Cyp1a2-sub | 0.73 |
| Cyp2c19-inh | 0.619 |
| Cyp2c19-sub | 0.27 |
| Cl | 9.1 |
| T12 | 0.021 |
| H-ht | 0.56 |
| Dili | 0.881 |
| Roa | 0.306 |
| Fdamdd | 0.92 |
| Skinsen | 0.772 |
| Ec | 0.003 |
| Ei | 0.047 |
| Respiratory | 0.489 |
| Bcf | 1.802 |
| Igc50 | 5.199 |
| Lc50 | 6.207 |
| Lc50dm | 5.856 |
| Nr-ar | 0.389 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.366 |
| Nr-aromatase | 0.777 |
| Nr-er | 0.295 |
| Nr-er-lbd | 0.015 |
| Nr-ppar-gamma | 0.007 |
| Sr-are | 0.655 |
| Sr-atad5 | 0.023 |
| Sr-hse | 0.671 |
| Sr-mmp | 0.369 |
| Sr-p53 | 0.759 |
| Vol | 378.313 |
| Dense | 0.884 |
| Flex | 0.286 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 3 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.504 |
| Synth | 1.95 |
| Fsp3 | 0.478 |
| Mce-18 | 43.588 |
| Natural product-likeness | -1.022 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |